1. Indications and Usage
\nRecurrent or Refractory Follicular Lymphoma (FL):
\nIndicated for the treatment of adult patients with recurrent or refractory follicular lymphoma who have received at least two prior systemic therapies.
\n2. Dosage and Administration
\nRecommended Dosage:
\nDose: 80 mg once daily (equivalent to four 20 mg tablets).
\nDuration: Continue treatment until disease progression or unacceptable toxicity.
\nAdministration: Administer orally with or without food.
\nProphylaxis:
\nPJP Prevention: Patients should receive prophylaxis for Pneumocystis jirovecii pneumonia (PJP) during treatment and after treatment until the absolute CD4+ T-lymphocyte count is greater than 200 cells\/\u00b5L.
\nCMV Prevention: Consider prophylactic antiviral therapy to prevent cytomegalovirus (CMV) infection and reactivation.
\n3. Mechanism of Action
\nPI3K\u03b4 Inhibitor:
\nLinperlisib is a highly selective inhibitor of the phosphoinositide 3-kinase delta (PI3K\u03b4) isoform.
\nPhysiological Effect:
\nIt inhibits the expression of the PI3K\u03b4 protein and reduces the phosphorylation of AKT protein. This inhibition induces apoptosis and suppresses the proliferation of malignant B cells and primary tumor cells.
\n4. Safety and Warnings
\nPneumocystis Pneumonia (PJP):
\nPJP can occur during treatment. Monitor patients for signs of PJP. Discontinue linperlisib in patients with suspected PJP and terminate in those with confirmed PJP.
\nInfections and Cytopenias:
\nMonitor blood counts and watch for signs of infection, including non-infectious pneumonia and severe neutropenia.
\nHepatotoxicity:
\nElevations in transaminases (ALT\/AST) may occur. Monitor liver function regularly.
\nSkin Reactions:
\nSkin reactions may occur; monitor and manage accordingly.
\n5. Adverse Reactions
\nMost Common:
\nLeukopenia (decreased white blood cell count), neutropenia, increased transaminases, thrombocytopenia, anemia, diarrhea, and colitis.
\n6. Drug Interactions
\nMetabolic Interactions:
\nLinperlisib is metabolized by hepatic enzymes. Caution is advised when used with CYP3A inhibitors or inducers.
\nContraindications:
\nContraindicated in patients with known hypersensitivity to linperlisib or any excipients.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Linperlisib. Molecular Formula: C\u2082\u2088H\u2083\u2087FN\u2086O\u2085S. Molecular Weight: 588.69.
\nStorage:
\nStore in the original package to protect from light and moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u56e0\u4ed6\u745e\u00ae( Yintarui\u00ae)
\nGeneric Name: Linperlisib
\nStrength: 20mg per tablet, 120 tablets per bottle
\nManufacturer: Jiangsu Xuantai Pharmaceutical Co., Ltd.
\nMarketing Authorization Holder: Shanghai Yingli Pharmaceutical Co., Ltd.
\nApproval Date in China: November 09, 2022
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 H20220030
\nStorage: Sealed, store in dry place at temperature not exceeding 30\u2103, keep away from children<\/p>\n
Price&Cost:Contact Us now for the best price of Linperlisib\uff08 Yintarui\uff09<\/p>\n","protected":false},"featured_media":3278,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27,73],"product_tag":[],"class_list":["post-3274","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n